Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL7784665 | 0.98 | ADRB2 (0.40) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1618292 | 0.94 | SMN1; SMN2 (0.44) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL9949255 | 0.94 | SMN1; SMN2 (0.44) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1619826 | 0.92 | LMNA (0.46) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL7968807 | 0.89 | ADRB2 (0.42) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL2195745 | 0.89 | ALDH1A1 (0.38) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL10496376 | 0.88 | LMNA (0.46) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL1619443 | 0.88 | SMN1; SMN2 (0.48) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL5052257 | 0.86 | SMN1; SMN2 (0.32) | ALDH1A1ADRB2SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL24337442 | 0.86 | ADRB2 (0.42) | ALDH1A1ADRB2TSHRADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609101-A1 | PROCESS FOR THE PREPARATION OF 3-(N-METHYL-N-PENTYL)AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONIC ACID SALT OR DERIVATIVES THEREOF | Pharmathen S.A. (GR) | 2013-07-03 | — | — | EP | claimed |
| WO-2012007021-A1 | PROCESS FOR THE PREPARATION OF 3-(N-METHYL-N-PENTYL)AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONIC ACID SALT OR DERIVATIVES THEREOF | PHARMATHEN S.A. (GR) | 2012-01-19 | — | — | WO | claimed |
| EP-1848728-A1 | IBANDRONATE POLYMORPH A | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-31 | — | — | EP | claimed |
| WO-2006081963-A1 | IBANDRONATE POLYMORPH A | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | claimed |
| US-9409119-B2 | Acid gas absorbent, acid gas removal method, and acid gas removal device | KABUSHIKI KAISHA TOSHIBA (JP) | 2016-08-09 | — | — | US | disclosed |
| EP-2705894-A1 | Acid gas absorbent, acid gas removal method and acid gas removal device | Kabushiki Kaisha Toshiba (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2609101-A1 | PROCESS FOR THE PREPARATION OF 3-(N-METHYL-N-PENTYL)AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONIC ACID SALT OR DERIVATIVES THEREOF | Pharmathen S.A. (GR) | 2013-07-03 | — | — | EP | disclosed |
| US-20120161071-A1 | ACID GAS ABSORBENT, ACID GAS REMOVAL METHOD, AND ACID GAS REMOVAL DEVICE | KABUSHIKI KAISHA TOSHIBA (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2468385-A2 | Acid gas absorbent, acid gas removal method and acid gas removal device | Kabushiki Kaisha Toshiba (JP) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012007021-A1 | PROCESS FOR THE PREPARATION OF 3-(N-METHYL-N-PENTYL)AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONIC ACID SALT OR DERIVATIVES THEREOF | PHARMATHEN S.A. (GR) | 2012-01-19 | — | — | WO | disclosed |
| EP-2144919-A2 | MULTI STEP SYNTHESIS OF IBANDRONATE | F. Hoffmann-Roche AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008125483-A2 | MULTI STEP SYNTHESIS OF IBANDRONATE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-5817638-A | USING HYBRID NUCLEOSIDES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5780617-A | PHOSPHORYLATION OF A PHOSPHATIDES WITH A NUCLEOTIDES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0594677-A4 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0594677-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | NeXstar Pharmaceuticals, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0531452-A4 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | — | 1993-06-09 | — | — | EP | disclosed |
| EP-0531452-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | NeXstar Pharmaceuticals, Inc. (US) | 1993-03-17 | — | — | EP | disclosed |
| WO-1993000910-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| WO-1991018914-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | VICAL, INC. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120161071-A1 | ACID GAS ABSORBENT, ACID GAS REMOVAL METHOD, AND ACID GAS REMOVAL DEVICE | ALKBH1, ALKBH3, ALKBH2 | ALDH1A1 247/4885ADRB2 1767/4885SMN1; SMN2 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.